Summit Therapeutics stock is trading -32.83% below its average target price of $32.5 after dropping -1.4% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $12.004937 to $49.326496 per share.
Summit Therapeutics has an elevated short interest of 27.6%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 6.87. The company's insiders own 84.34% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Summit Therapeutics's rate of institutional ownership is 13.5%, which indicates a decent level of confidence in the stock. Based on these factors, Market Inference considers Summit Therapeutics to be the target of mixed market sentiment.
Institutions Invested in Summit Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Baker Bros. Advisors, LP | 5% | 33,722,974 | $736,172,519 |
| 2025-06-30 | FMR, LLC | 1% | 9,226,376 | $201,411,787 |
| 2025-06-30 | Vanguard Group Inc | 1% | 8,673,672 | $189,346,259 |
| 2025-06-30 | Blackrock Inc. | 1% | 6,846,667 | $149,462,740 |
| 2025-06-30 | State Street Corporation | 1% | 4,017,697 | $87,706,325 |
| 2025-06-30 | Price (T.Rowe) Associates Inc | 1% | 3,905,148 | $85,249,380 |
| 2025-06-30 | Geode Capital Management, LLC | 0% | 2,934,815 | $64,067,011 |
| 2025-06-30 | Pictet Asset Management Holding SA | 0% | 2,163,873 | $47,237,347 |
| 2025-06-30 | UBS Group AG | 0% | 2,093,958 | $45,711,102 |
| 2025-06-30 | NORGES BANK | 0% | 1,389,862 | $30,340,687 |
